<DOC>
	<DOCNO>NCT01819558</DOCNO>
	<brief_summary>Patients acute chronic myeloid leukemia , myelodysplastic syndrome , underwent allogeneic stem cell transplantation HLA-identical donor ( relate unrelated ) reduced-intensity condition regimen . If WT1 expression detectable tumor cell , receive immune therapy 60 day allograft . 6 administration every 2 week protein recwt1-A10+AS01B administrate . The safety immunological efficacy immune therapy hematopoietic stem cell transplantation reduce intensity conditioning evaluate .</brief_summary>
	<brief_title>Phase I/II Study Immune Therapy After Allograft Patients With Myeloid Hemopathy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Patients older 18 young 65 year . 2 . Karnofsky ≥ 70 % . 3 . Patients acute chronic myeloid leukemia , myelodysplastic syndrome , underwent allogeneic stem cell transplantation HLAidentical donor ( relate unrelated ) reducedintensity condition regimen . 4 . Patients morphologic complete remission time transplantation . 5 . WT1 expression detectable tumor cell . 6 . Expected life duration 6 month . 7 . Creatinine clearance ≥ 50 ml/min 8 . Bilirubinemia &lt; 1.5N ASAT &lt; 2.5N . 9 . Women childbearing age : negative pregnancy test effective contraception least 30 day vaccinal immunotherapy ( contraceptive method must continue least 2 month last vaccine infusion ) . 10 . Membership social security scheme beneficiary regime . 11 . Signed inform consent . 1 . Patients severe uncontrolled affection , especially active graftversushost disease require steroid treatment ( &gt; 0.3 mg/kg/j ) and/or Mycophenolate mofetil . 2 . Pregnant lactating woman . 3 . HIV seropositive patient . 4 . Autoimmune disease ( Lupus , multiple sclerosis , Chron disease… ) 5 . Previous history allergic state could potentially compound component vaccinal immunotherapy . 6 . Patients receive ( plan receive ) another experimental treatment within 30 day follow first infusion experimental drug protocol . 7 . Previous history another cancer , except consider probably cured investigator . 8 . Patients deprive liberty , guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>allograft</keyword>
	<keyword>WT1 expression</keyword>
</DOC>